April 1, 2019
Lupin names new Independet Director
Pharma player Lupin Limited has appointed Christine Mundkur as an Independent Director with immediate effect, the company said Monday, recent CEO of Impopharma Inc.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
March 29, 2019
MedPharm to develop Destiny Pharma’s formulations from XF-platform
Destiny Pharma has picked MedPharm to develop new topical formulations of its novel XF-platform compounds, new treatments for dermal and ocular infections which are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR).
March 27, 2019
Novartis nets approval for Mayzent, first oral drug to treat secondary progressive RMS
Novartis on Wednesday said that it got approval from the FDA for Mayzent for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults.
March 22, 2019
Eisai, Biogen kick-off phase 3 testing early Alzheimer’s disease antibody, amid dropping aducanunab trial. Eisai’s US company presents AD pipeline
Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.
March 22, 2019
Neurotrope jumps in the Alzheimer’s solution chase, amid Biogen’s, Eisai’s dropping aducanunab trial
Neurotrope said Friday, commenting Biogen Inc.’s decision to discontinue its global Phase 3 trials of aducanunab in Alzheimer’s disease, Phase 2 clinical trial using its drug Bryostatin during the second half of 2019.
March 22, 2019
ProMIS offeri potential significant advantage over aducanumab, learns from mistakes
ProMIS Neurosciencesissued a pres release Friday, raising urgency to selectively target the toxic oligomer with exacting precision as part of the global effort to develop disease-modifying therapies for Alzheimer’s disease (AD), upon Biogen’s and Eisai’s dropping two alte-stage clinical trials of aducanumab.
March 21, 2019
Enzyvant to get RVT-801 available to Farber disease patients as quickly as possible after FDA’s nod
Enzyvant’s RVT-801, an investigational enzyme replacement therapy, was granted Rare Pediatric Disease and Fast Track designations by the FDA, the company said in a press release Thursday.
March 21, 2019
MatriSys closer to begin testing MSB-01 for Atopic Dermatitis, afer FDA’s positive feedback
MatriSys Bioscience got positive feedback from the FDA on its planned initiation of clinical trials for MSB-01 under a U.S. IND for MatriSys’ lead microbiome-based candidate, MSB-01, for the treatment of Atopic Dermatitis (AD).
March 21, 2019
Alvogen’s Taiwan company – Lotus – exchange stake with Fuji Pharma
@alvogenpr subsidiary in Taiwan, Lotus Pharmaceuticals today announced capital and business collaboration agreements with Fuji Pharma in Japan, as Fuji has acquired a 2.0% stake in Lotus for approximately US$20 million (or NT$ 617 million, JPY 2.2 billion). Lotus has also acquired 3.9% stake in Fuji for an equal sum.
March 21, 2019
Verona Pharma welcomes Non-Executive Director
Verona Pharma as Non-Executive Director